{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:28:24Z","timestamp":1792787304316,"version":"4.5.0"},"reference-count":40,"publisher":"BMJ","issue":"9","funder":[{"name":"2025 Clinical Research Youth Fund of West China Hospital, Sichuan University","award":["2025HXFH025"],"award-info":[{"award-number":["2025HXFH025"]}],"id":[{"id":"https:\/\/ror.org\/011ashp19","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370171"],"award-info":[{"award-number":["82370171"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Med Genet"],"accepted":{"date-parts":[[2026,5,17]]},"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Familial acute myeloid leukaemia (AML) with germline\n                      <jats:italic>CEBPA<\/jats:italic>\n                      (CCAAT\/enhancer-binding protein alpha) variants is a distinct hereditary entity, yet clinically meaningful genotype\u2013phenotype correlations remain incompletely defined.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We integrated cases from our institution with all published pedigrees of germline\n                      <jats:italic>CEBPA<\/jats:italic>\n                      -mutated AML and analysed 56 affected patients from 40 families, including one newly identified pedigree harbouring a novel TAD2 (transactivation domain 2) variant (p.C133Ter).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Variant localisation significantly influenced disease phenotype and outcome. Compared with non-TAD2 variants, TAD2 variants were associated with older age at AML onset (40 years vs 21 years, p&lt;0.001), a higher burden of cooperating somatic variants (64.3% vs 27.3%, p=0.023) and lower complete remission rates after induction therapy (69.2% vs 95.3%, p=0.022). TAD2 involvement conferred inferior overall survival (p&lt;0.001) and progression-free survival (p=0.025). In univariate analyses, TAD2 variants emerged as adverse prognostic factors for 2-year overall survival (OR=0.06, 95%\u2009CI 0.01 to 0.34, p=0.002) and progression-free survival (OR=0.07, 95%\u2009CI 0.01 to 0.35, p=0.003).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Although germline\n                      <jats:italic>CEBPA<\/jats:italic>\n                      -mutated AML is generally regarded as favourable-risk, TAD2-involving variants may define a biologically and clinically high-risk subset, supporting variant topography as a clinically actionable prognostic marker.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jmg-2026-111543","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T17:20:42Z","timestamp":1779988842000},"page":"596-604","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Location matters: topography of germline\n                    <i>CEBPA<\/i>\n                    variants predicts variable outcomes in familial acute myeloid leukaemia\u2014a rare disease perspective"],"prefix":"10.1136","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8998-8796","authenticated-orcid":false,"given":"Jinjun","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Hematology and Institute of Hematology, West China Hospital of Sichuan University, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqian","family":"Duan","sequence":"additional","affiliation":[{"name":"Department of Hematology and Institute of Hematology, West China Hospital of Sichuan University, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Hematology and Institute of Hematology, West China Hospital of Sichuan University, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Hematology and Institute of Hematology, West China Hospital of Sichuan University, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"2026102307200989000_63.9.596.1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1146\/annurev-pathmechdis-111523-023420","article-title":"Inherited Predispositions to Myeloid Neoplasms: Pathogenesis and Clinical Implications","volume":"20","author":"Liu","year":"2025","journal-title":"Annu Rev Pathol"},{"key":"2026102307200989000_63.9.596.2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-142513"},{"key":"2026102307200989000_63.9.596.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041331"},{"key":"2026102307200989000_63.9.596.4","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403788"},{"key":"2026102307200989000_63.9.596.5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-05-647172"},{"key":"2026102307200989000_63.9.596.6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544"},{"key":"2026102307200989000_63.9.596.7","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.4.1234.bloodjournal8841234"},{"key":"2026102307200989000_63.9.596.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcb.2007.07.004"},{"key":"2026102307200989000_63.9.596.9","doi-asserted-by":"publisher","DOI":"10.1038\/nri2024"},{"key":"2026102307200989000_63.9.596.10","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006910"},{"key":"2026102307200989000_63.9.596.11","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.130799"},{"key":"2026102307200989000_63.9.596.12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.5563"},{"key":"2026102307200989000_63.9.596.13","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.294"},{"key":"2026102307200989000_63.9.596.14","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/gcc.20734","article-title":"A family harboring a germ-line N-terminal C\/EBPalpha mutation and development of acute myeloid leukemia with an additional somatic C-terminal C\/EBPalpha mutation","volume":"49","author":"Nanri","year":"2010","journal-title":"Genes Chromosomes Cancer"},{"key":"2026102307200989000_63.9.596.15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-326322"},{"key":"2026102307200989000_63.9.596.16","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.64"},{"key":"2026102307200989000_63.9.596.17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-09-307280"},{"key":"2026102307200989000_63.9.596.18","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.082578"},{"key":"2026102307200989000_63.9.596.19","doi-asserted-by":"crossref","first-page":"106933","DOI":"10.1016\/j.leukres.2022.106933","article-title":"Acquired somatic variants confirm the independent development of AML in monozygotic twins with germline CEBPA variant","volume":"121","author":"Podgornik","year":"2022","journal-title":"Leuk Res"},{"key":"2026102307200989000_63.9.596.20","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017004424"},{"key":"2026102307200989000_63.9.596.21","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.leukres.2018.12.003","article-title":"Germline CEBPA mutations in Korean patients with acute myeloid leukemia","volume":"76","author":"Kim","year":"2019","journal-title":"Leuk Res"},{"key":"2026102307200989000_63.9.596.22","first-page":"1008","article-title":"Investigation and clinical analysis of a family with germline CEBPA mutations in acute myeloid leukemia","volume":"41","author":"Zhang","year":"2020","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"2026102307200989000_63.9.596.23","first-page":"6965","article-title":"Identification of novel CEBPA double mutations capable of promoting familial AML via the suppression of myeloid differentiation","volume":"12","author":"Zheng","year":"2020","journal-title":"Am J Transl Res"},{"key":"2026102307200989000_63.9.596.24","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1080\/10428194.2020.1861276","article-title":"A case of acute myeloid leukemia with unusual germline CEBPA mutation: lessons learned about mutation detection, location, and penetrance","volume":"62","author":"Mendoza","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"2026102307200989000_63.9.596.25","doi-asserted-by":"crossref","DOI":"10.4081\/hr.2021.9114","article-title":"Germline CEBPA mutation in familial acute myeloid leukemia","volume":"13","author":"Boada","year":"2021","journal-title":"Hematol Rep"},{"key":"2026102307200989000_63.9.596.26","doi-asserted-by":"crossref","DOI":"10.1002\/mgg3.1854","article-title":"Acute myeloid leukemia due to germline CEBPA mutation in a Syrian family","volume":"10","author":"Wafa","year":"2022","journal-title":"Mol Genet Genomic Med"},{"key":"2026102307200989000_63.9.596.27","doi-asserted-by":"crossref","first-page":"S417","DOI":"10.1016\/j.htct.2024.07.004","article-title":"Familial acute myeloid leukemia due to a novel germline CEBPA pathogenic variant - a case report","volume":"46 Suppl 6","author":"Gava","year":"2024","journal-title":"Hematol Transfus Cell Ther"},{"key":"2026102307200989000_63.9.596.28","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/cge.14693","article-title":"Unusual Co-Occurrence of Multiple Myeloma and AML in a Patient With Germline CEBPA Variant. Expanding the Spectrum of Hereditary Hematologic Malignancies","volume":"107","author":"Spangenberg","year":"2025","journal-title":"Clin Genet"},{"key":"2026102307200989000_63.9.596.29","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s10689-023-00329-0","article-title":"Hereditary acute myeloid leukemia associated with C-terminal CEBPA germline variants","volume":"22","author":"Harrigan","year":"2023","journal-title":"Fam Cancer"},{"key":"2026102307200989000_63.9.596.30","doi-asserted-by":"crossref","unstructured":"Demaret T , Feret D , Lambert B , et al . CEBPA-associated familial acute myeloid leukemia mimicking Werner syndrome: a case report. Front Genet 2025;16. doi:10.3389\/fgene.2025.1575651","DOI":"10.3389\/fgene.2025.1575651"},{"key":"2026102307200989000_63.9.596.31","doi-asserted-by":"crossref","first-page":"107453","DOI":"10.1016\/j.leukres.2024.107453","article-title":"Clinical features and management of germline CEBPA-mutated carriers","volume":"138","author":"Pan","year":"2024","journal-title":"Leuk Res"},{"key":"2026102307200989000_63.9.596.32","doi-asserted-by":"crossref","first-page":"21111","DOI":"10.1002\/cam4.6669","article-title":"The clinical features and prognostic implications of PTPN11 mutation in adult patients with acute myeloid leukemia in China","volume":"12","author":"Yang","year":"2023","journal-title":"Cancer Med"},{"key":"2026102307200989000_63.9.596.33","first-page":"705","article-title":"Chinese guidelines for diagnosis and treatment of adult acute myeloid leukemia (not APL) (2023)","volume":"44","year":"2023","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"2026102307200989000_63.9.596.34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06909.x"},{"key":"2026102307200989000_63.9.596.35","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1363"},{"key":"2026102307200989000_63.9.596.36","unstructured":"Fernanda MR , Nadezhda VT , Kathleen JI , et al . Precision proteogenomics reveals pan-cancer impact of germline variants. Cell 2025;188."},{"key":"2026102307200989000_63.9.596.37","unstructured":"Board P . CEBPA-Associated Familial Acute Myeloid Leukemia (PDQ): Health Professional Version. PDQ Cancer Information Summaries. Bethesda (MD): National Cancer Institute (US), 2002."},{"key":"2026102307200989000_63.9.596.38","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.19"},{"key":"2026102307200989000_63.9.596.39","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2017.04.001"},{"key":"2026102307200989000_63.9.596.40","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12317"}],"container-title":["Journal of Medical Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jmg-2026-111543","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T14:20:36Z","timestamp":1792765236000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmg.bmj.com\/lookup\/doi\/10.1136\/jmg-2026-111543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":40,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,8,26]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1136\/jmg-2026-111543"],"URL":"https:\/\/doi.org\/10.1136\/jmg-2026-111543","relation":{},"ISSN":["0022-2593","1468-6244"],"issn-type":[{"value":"0022-2593","type":"print"},{"value":"1468-6244","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]}}}